<< Metiscan closes equity funding of $7.3M | Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic >>
Read in | English | Español | Ελληνικά

Praxair's 3.250% notes offering expected to close on September 1, 2009

Published on August 28, 2009 at 8:31 AM · No Comments

Praxair, Inc. (NYSE:PX) has priced $400 million of 3.250% notes due September 15, 2015. The notes are being offered under its universal shelf registration statement filed with the U.S. Securities and Exchange Commission. The offering is led by Citigroup Global Markets Inc. and RBS Securities Inc.

The offering is expected to close on September 1, 2009. The company anticipates using the proceeds of the offering to repay short-term debt and for general corporate purposes. Prior to their application, the net proceeds may be invested in short-term investments. The company’s long-term debt is rated A2 by Moody’s Investors Service and A by Standard and Poor’s Corporation.

http://www.praxair.com 

Posted in:

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading